Sigachi Industries begins disbursing Interim ex-gratia to families of deceased

EMA’s CHMP recommends authorization of Moderna's Covid-19 vaccine Spikevax for SARS-CoV-2 Variant LP.8.1

Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision

Laurus Labs to invest €5 million in JV KRKA Pharma

The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility

RPG Life Sciences appoints Deepak Shukla as Chief Executive - API Business

Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories

Alembic Pharmaceuticals announces USFDA final approval for Carbamazepine ER Tablets USP

Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug

Concord Biotech successfully completes Russian GMP inspection at its API facility

The inspection was conducted from July 22-25, 2025

Jagsonpal Pharmaceuticals Q1 FY26 revenue up 23.1%

Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution

Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary

The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%

Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr

Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025

Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025